Halozyme's proprietary ENHANZE® drug delivery technology is based on its patented recombinant human hyaluronidase enzyme (rHuPH20). Using rHuPH20 enables some biologics to be delivered rapidly in large volumes subcutaneously, which can potentially improve efficiencies for healthcare systems, reduce overall administration time and may reduce the treatment burden for patients.